ArticleJournal of neuroinflammation2026
Nebulized bone marrow-derived stem cell supernatant induces tolerogenic dendritic cells via upregulation of FOXO3 for EAE treatment.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBone marrow mesenchymal stem cells (BMSCs) exert potent paracrine effects that can reshape the immune microenvironment. Nebulized inhalation enables non-invasive, targeted delivery to the lung, a pivotal immune interface capable of modulating systemic immunity. This study introduces a novel therapeutic strategy using nebulized BMSC supernatant to activate the FOXO3 signaling pathway in pulmonary dendritic cells (DCs), reprogramming them toward a tolerogenic phenotype. This approach suppresses autoreactive T cell infiltration and alleviates central nervous system (CNS) inflammation in the experimental autoimmune encephalomyelitis (EAE) model, offering a potential acellular therapy for multiple sclerosis (MS) and other autoimmune diseases.
methodsEAE mice were treated with nebulized BMSC supernatant or adoptive transfer of pretreated DCs. Disease progression was assessed by body weight and clinical scores. Hematoxylin and eosin (HE) staining and myelin immunofluorescence staining were used to evaluate CNS inflammation and demyelination. Flow cytometry measured T cell differentiation in spleen and lymph nodes, as well as DC antigen presentation and cytokine secretion in lung tissue. Quantitative Polymerase Chain Reaction (QPCR) assessed inflammatory cytokines, and immunofluorescence determined FOXO3 expression in DCs. FOXO3 involvement was validated using inhibitor-pretreated DCs in adoptive transfer experiments.
resultsNebulized BMSC supernatant reduced clinical severity and weight loss in EAE mice, and decreased CNS inflammatory infiltration and demyelination. Treatment suppressed peripheral Th1 and Th17 differentiation while increasing Treg frequency. Lung DCs exhibited reduced antigen presentation and pro-inflammatory cytokine expression, increased IL-10 secretion, and elevated FOXO3 expression. Blocking FOXO3 in DCs reversed these effects, aggravating EAE symptoms and promoting Th1/Th17 differentiation.
conclusionsNebulized BMSC supernatant effectively treats EAE by inducing pulmonary tolerogenic dendritic cells (tolDC) via FOXO3 activation, reshaping peripheral T cell responses, and reducing CNS inflammation. This strategy highlights the therapeutic potential of targeting the pulmonary immune interface as a novel acellular approach for MS and related autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.